The role of hormonal therapy in gynecological cancers - Current status and future directions

International Journal of Gynecological Cancer

Volumn 21, Issue 7, 2011, Pages 1328-1333

  Sjoquist, Katrin M ^a,b   Martyn, Julie ^a,b   Edmondson, Richard J ^c   Friedlander, Michael L ^b,d,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Australia and New Zealand Gynaecological Oncology Group   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Aromatase inhibitors; Endometrial neoplasms; Gynecological neoplasms; Hormonal therapy; Ovarian neoplasms

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; AROMATASE INHIBITOR; CA 125 ANTIGEN; ESTROGEN RECEPTOR; GESTAGEN; LETROZOLE; LEUPRORELIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; DRUG RESPONSE; ENDOMETRIUM CANCER; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GRANULOSA CELL TUMOR; GYNECOLOGIC CANCER; HUMAN; HYPERTENSION; INSOMNIA; LUNG EMBOLISM; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SIDE EFFECT; THROMBOSIS; TREMOR; UTERUS SARCOMA; WEIGHT GAIN; CARCINOMA; FEMALE; FEMALE GENITAL TRACT TUMOR; HORMONE SUBSTITUTION; SARCOMA;

AROMATASE INHIBITORS; CARCINOMA; FEMALE; GENITAL NEOPLASMS, FEMALE; GRANULOSA CELL TUMOR; HORMONE REPLACEMENT THERAPY; HUMANS; SARCOMA;

EID: 84856068538     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821d6021     Document Type: Review

References (34)

1. Kelley TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol. 2004;12:338-341. (Pubitemid 39602073)
2. Abu-Jawdeh GM, Jacobs TW, Niloff J, et al. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol. 1996;60:301-307. (Pubitemid 26058778)
3. Walker G, MacLeod K, Williams AR, et al. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol. 2007;106:461-468. (Pubitemid 47302473)
4. Ioffe YJ, Li AJ, Walsh CS, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115:466-471.
5. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14:357-361. (Pubitemid 26050995)
6. Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2001;1:CD001034.
7. Karagol H, Saip P, Uygun K, et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol. 2007;24:39-43.
8. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod. 1994;9:1364-1379. (Pubitemid 24224014)
9. Fishman A, Kudelka AP, Tresukosol D, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med. 1996;41:393-396. (Pubitemid 26192479)
10. Krasner C. Aromatase inhibitors in gynecologic cancers. J Steroid Biochem Mol Biol. 2007;106:76-80. (Pubitemid 47362641)
11. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology (Williston). 2004;66:112-117. (Pubitemid 38608377)
12. Garrett A, Quinn MA. Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol. 2008;22:407-421. (Pubitemid 351292329)
13. Hatch KD, Beecham JB, Blessing JA, et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991;68:269-271.
14. Reich O, Regauer S. Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol. 2007;19:347-352. (Pubitemid 46883524)
15. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009;(4):CD003370.
16. Bowman A, Gabra H, Langdon S, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002;8:2233-2239. (Pubitemid 34753595)
17. Langdon SP, Smyth JF. Hormone therapy for epithelial ovarian cancer. Curr Opin Oncol. 2008;20:548-553.
18. Bellone S, Shah HR, McKenney JK, et al. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol. 2008;199:e7-e10.
19. Dahhan T, Fons G, Buist MR, et al. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur J Obstet Gynecol Reprod Biol. 2009;144:80-84.
20. Korach J, Perri T, Beiner M, et al. Promising effect of aromatase inhibitors on recurrent granulosa cell tumors. Int J Gynecol Cancer. 2009;19:830-833.
21. Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptorYpositive patients. Clin Cancer Res. 2007;13:3617-3622. (Pubitemid 46955124)
22. Hogdall EV, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep. 2007;18:1051-1059.
23. Rustin GJS. Use of CA-125 to assess response to new agents in ovarian cancer trials.JClinOncol. 2003;21(suppl 10):187-193.
24. Ramirez PT, Schmeler KM, Milam MR, et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008;110:56-59.
25. Rustin G, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.
26. Gynecological Cancer Intergroup G, du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16(suppl 8):viii7-viii12.
27. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17:964-978. (Pubitemid 47414814)
28. Reich O, Regauer S. Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol. 2004;17:104-108. (Pubitemid 41656459)
29. Spano JP, Soria JC, Kambouchner M, et al. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol. 2003;20:87-93. (Pubitemid 36344030)
30. O'Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116:424-429.
31. Sylvestre V, Dunton C. Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review. Horm Cancer. 2010;1:112-115.
32. Savage P, Constenla D, Fisher C, et al. Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Clin Oncol (R Coll Radiol). 1998;10:242-245. (Pubitemid 28454544)
33. Jobling T, Mamers P, Healy D L, et al. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol. 1994;55:285-289. (Pubitemid 24366640)
34. Hardy RD, Bell JG, Nicely CJ, et al. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol. 2005;96:865-869. (Pubitemid 40255516)